Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment

Aims The biochemical response after ursodeoxycholic acid (UDCA) treatment contributes toward predicting the prognosis for primary biliary cholangitis (PBC) patients. This study aimed to establish a score model that can be used for predicting the biochemical response. Patients and methods A total of 218 patients in the derivation group and 66 patients in the verification group were enrolled. Response endpoints were based on the Barcelona criteria combined with the Paris I criteria. We determined independent factors of the biochemical response by univariate and multivariate analyses. Then, we established a predictive score model on the basis of regression coefficients after adjusted multivariate analyses. Results The median follow-up duration in the derivation and the verification group was 12.9 and 12.2 months, respectively. Multivariate logistic regression analysis after adjusting for sex and age indicated that First-UDCA treatment [odds ratio (OR)=2.543, 95% confidence interval (CI): 1.234–5.240, P=0.011], baseline alanine aminotransferase level (OR=1.265, 95% CI: 1.089–1.471, P=0.002), and baseline total bilirubin level (OR=0.571, 95% CI: 0.420–0.776, P<0.001) were independent factors that influenced the biochemical response in PBC patients after 1 year of UDCA treatment. Therefore, the resulting biochemical response prediction score model represented the sum of the points corresponding to these three variables. The area under the receiver operating characteristic curve of the score model in the derivation group and the verification group was 0.763 (95% CI: 0.701–0.817, P<0.001) and 0.798 (95% CI: 0.681–0.887, P<0.001), respectively. Conclusion We developed and verified an easy-to-use scoring model for the first time, which showed excellent predictive value for the biochemical response in PBC patients.

[1]  M. Yuen,et al.  Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis , 2017, World journal of gastroenterology.

[2]  G. Hirschfield,et al.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.

[3]  J. Reguła,et al.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[4]  Fengchun Zhang,et al.  Therapeutic advances for primary biliary cholangitis: the old and the new , 2016, European journal of gastroenterology & hepatology.

[5]  S. Milani,et al.  Assessment of liver fibrosis in primary biliary cholangitis: Comparison between indirect serum markers and fibrosis morphometry. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[6]  P. Invernizzi,et al.  Making Sense of Autoantibodies in Cholestatic Liver Diseases. , 2016, Clinics in liver disease.

[7]  I. Mackay,et al.  Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. , 2015, Journal of hepatology.

[8]  V. Wong,et al.  New simple prognostic score for primary biliary cirrhosis: Albumin‐bilirubin score , 2015, Journal of gastroenterology and hepatology.

[9]  T. Saibara,et al.  Autoantibody status and histological variables influence biochemical response to treatment and long‐term outcomes in Japanese patients with primary biliary cirrhosis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  L. Cui,et al.  Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis , 2015, Alimentary pharmacology & therapeutics.

[11]  K. Lindor,et al.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.

[12]  K. Lindor,et al.  Primary biliary cirrhosis , 2003, The Lancet.

[13]  A. Burroughs,et al.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.

[14]  K. Lindor,et al.  The Natural History of Primary Biliary Cirrhosis , 2014, Seminars in Liver Disease.

[15]  E. Atkinson,et al.  Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients , 2014, Journal of Gastroenterology.

[16]  A. Burroughs,et al.  Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study , 2013, Alimentary pharmacology & therapeutics.

[17]  B. Liu,et al.  Early biochemical response to ursodeoxycholic acid and long‐term prognosis of primary biliary cirrhosis: Results of a 14‐year cohort study , 2013, Hepatology.

[18]  G. Alexander,et al.  Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. , 2013, Gastroenterology.

[19]  K. Hino,et al.  Risk factors for survival and the development of hepatocellular carcinoma in patients with primary biliary cirrhosis. , 2013, Internal medicine.

[20]  C. Selmi,et al.  Serum autoantibodies for the diagnosis and management of autoimmune liver diseases , 2012, Expert review of gastroenterology & hepatology.

[21]  V. Novack,et al.  Primary biliary cirrhosis in Southern Israel: a 20 year follow up study. , 2012, European journal of internal medicine.

[22]  R. Poupon Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. , 2012, Clinics and research in hepatology and gastroenterology.

[23]  O. Chazouilleres,et al.  Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.

[24]  A. Takaki,et al.  Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid , 2011, Journal of gastroenterology and hepatology.

[25]  Y. Hiasa,et al.  Biochemical response to ursodeoxycholic acid predicts long‐term outcome in Japanese patients with primary biliary cirrhosis , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[26]  R. Chapman,et al.  28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC , 2011 .

[27]  Shou-Dong Lee,et al.  Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis , 2009, Journal of clinical gastroenterology.

[28]  K. V. van Erpecum,et al.  Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. , 2009, Gastroenterology.

[29]  M. Kaplan,et al.  Primary biliary cirrhosis , 1998, Hepatology.

[30]  F. Lammert,et al.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases. , 2009, Journal of hepatology.

[31]  Y. Chrétien,et al.  Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.

[32]  B. Hansen,et al.  Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients , 2006, The American Journal of Gastroenterology.

[33]  J. Rodés,et al.  Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.

[34]  F. Carrat,et al.  The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. , 2005, Gastroenterology.

[35]  E. Dickson,et al.  Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) , 1978, Virchows Archiv A.

[36]  T. Therneau,et al.  Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. , 1999, Liver.

[37]  P. Grambsch,et al.  Prognosis in primary biliary cirrhosis: Model for decision making , 1989, Hepatology.

[38]  F. Schaffner,et al.  Serum bilirubin: a prognostic factor in primary biliary cirrhosis. , 1979, Gut.